Gastrointestinal stromal tumor mesenchymal neoplasms: the offspring that choose the wrong path

Gastrointestinal stromal tumor mesenchymal neoplasms: the offspring that choose the wrong path

Gastrointestinal stromal tumors (GISTs) are relatively rare neoplasms of the gastrointestinal tract originating from the pluripotential mesenchymal stem cells, which differentiate into interstitial Cajal cells. They are usually located in the upper gastrointestinal track. These tumors are typically...

Full description

Bibliographic Details
Main Authors: Machairiotis, Nikolaos, Kougioumtzi, Ioanna, Zarogoulidis, Paul, Stylianaki, Aikaterini, Tsimogiannis, Konstantinos, Katsikogiannis, Nikolaos
Format: Online
Language:English
Published: Dove Medical Press 2013
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3621649/
id pubmed-3621649
recordtype oai_dc
spelling pubmed-36216492013-04-11 Gastrointestinal stromal tumor mesenchymal neoplasms: the offspring that choose the wrong path Machairiotis, Nikolaos Kougioumtzi, Ioanna Zarogoulidis, Paul Stylianaki, Aikaterini Tsimogiannis, Konstantinos Katsikogiannis, Nikolaos Expert Opinion Gastrointestinal stromal tumors (GISTs) are relatively rare neoplasms of the gastrointestinal tract originating from the pluripotential mesenchymal stem cells, which differentiate into interstitial Cajal cells. They are usually located in the upper gastrointestinal track. These tumors are typically defined by the expression of c-KIT (CD117) and CD34 proteins in the tumor cells. A small percentage of these tumors is negative for c-KIT. The neoplasms are positive for platelet-derived growth factor α (PDGFα) mutations. In addition to PDGFRα mutations, wild-type c-KIT mutations can also be present. The therapeutic approach to locally developed gastrointestinal stromal tumors is surgical resection, either with open or laparoscopic surgery. In case of systemic disease, molecular pharmacologic agents such as imatinib and sunitinib are used for treatment. These agents block the signaling pathways of neoplastic-cell tyrosine kinases, interfering in their proliferation and causing apoptosis. Dove Medical Press 2013-03-31 /pmc/articles/PMC3621649/ /pubmed/23579364 http://dx.doi.org/10.2147/JMDH.S43703 Text en © 2013 Machairiotis et al, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Machairiotis, Nikolaos
Kougioumtzi, Ioanna
Zarogoulidis, Paul
Stylianaki, Aikaterini
Tsimogiannis, Konstantinos
Katsikogiannis, Nikolaos
spellingShingle Machairiotis, Nikolaos
Kougioumtzi, Ioanna
Zarogoulidis, Paul
Stylianaki, Aikaterini
Tsimogiannis, Konstantinos
Katsikogiannis, Nikolaos
Gastrointestinal stromal tumor mesenchymal neoplasms: the offspring that choose the wrong path
author_facet Machairiotis, Nikolaos
Kougioumtzi, Ioanna
Zarogoulidis, Paul
Stylianaki, Aikaterini
Tsimogiannis, Konstantinos
Katsikogiannis, Nikolaos
author_sort Machairiotis, Nikolaos
title Gastrointestinal stromal tumor mesenchymal neoplasms: the offspring that choose the wrong path
title_short Gastrointestinal stromal tumor mesenchymal neoplasms: the offspring that choose the wrong path
title_full Gastrointestinal stromal tumor mesenchymal neoplasms: the offspring that choose the wrong path
title_fullStr Gastrointestinal stromal tumor mesenchymal neoplasms: the offspring that choose the wrong path
title_full_unstemmed Gastrointestinal stromal tumor mesenchymal neoplasms: the offspring that choose the wrong path
title_sort gastrointestinal stromal tumor mesenchymal neoplasms: the offspring that choose the wrong path
description Gastrointestinal stromal tumors (GISTs) are relatively rare neoplasms of the gastrointestinal tract originating from the pluripotential mesenchymal stem cells, which differentiate into interstitial Cajal cells. They are usually located in the upper gastrointestinal track. These tumors are typically defined by the expression of c-KIT (CD117) and CD34 proteins in the tumor cells. A small percentage of these tumors is negative for c-KIT. The neoplasms are positive for platelet-derived growth factor α (PDGFα) mutations. In addition to PDGFRα mutations, wild-type c-KIT mutations can also be present. The therapeutic approach to locally developed gastrointestinal stromal tumors is surgical resection, either with open or laparoscopic surgery. In case of systemic disease, molecular pharmacologic agents such as imatinib and sunitinib are used for treatment. These agents block the signaling pathways of neoplastic-cell tyrosine kinases, interfering in their proliferation and causing apoptosis.
publisher Dove Medical Press
publishDate 2013
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3621649/
_version_ 1611969017320308736

Similar Items